Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.

Current opinion in hematology - 1 Mar 2023

Maggioni Giulia, Della Porta Matteo G

Abstract excerpt

PURPOSE OF REVIEW: The aim of this review is to provide a complete perspective of the evidence that led to the three recent new landmarks of myelodysplastic syndromes (MDS) definition and prognostication: the WHO 2022 and International Consensus Classification (ICC) 2022 classification and the Molecular Intermational Prognostic Scoring System (IPSS-M) score. RECENT FINDINGS: The molecular founding lesions of MDS...

Topics

Humans
Myelodysplastic Syndromes
Prognosis
Mutation
Phenotype
Leukemia, Myeloid, Acute

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 36728601
DOI: 10.1097/MOH.0000000000000752

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.PMID 36728601Read ↗

Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.Semantic proximity Read ↗

Impact of the International Consensus Classification of myelodysplastic syndromes.Semantic proximity Read ↗

Validation of the Molecular International Prognostic Scoring System in Patients with Myelodysplastic Syndromes Defined by International Consensus ClassificationSemantic proximity Read ↗

Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.Semantic proximity Read ↗

Diagnosis and classification of myelodysplastic syndromesSemantic proximity Read ↗

A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms.Semantic proximity Read ↗

[Molecular international prognostic scoring system for myelodysplastic syndromes].Semantic proximity Read ↗

Reclassification of Myelodysplastic Neoplasms According to the 2022 World Health Organization Classification and the 2022 International Consensus Classification Using Open-Source Data: Focus on SF3B1- and TP53-mutated Myelodysplastic Neoplasms.Semantic proximity Read ↗

Myelodysplastic Neoplasms (MDS): The Current and Future Treatment LandscapeSemantic proximity Read ↗

When to use which molecular prognostic scoring system in the management of patients with MDS?Semantic proximity Read ↗

Comparison of the 2022 World Health Organization Classification and International Consensus Classification in Myelodysplastic Syndromes/NeoplasmsSemantic proximity Read ↗

The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.